Study Conduct

Consortium hopes to make clinical trials more diverse

Sunday, November 15, 2015

Second of two parts

Over the past 20 years, the com­bined efforts of Congress, along with the offices of women’s health at FDA and NIH, have increased the participation of women in clinical tri­als. Minorities, however, still account for less than 5% of clinical trial partici­pants. In fact, minorities “are not hard to reach; they are hardly reached” (Lu Chen, HealthDay News, March 2014).

[Read More]

Parexel, Kyoto ink agreement for Japan’s biopharmaceutical workforce

Friday, November 13, 2015

Parexel International, a global biopharmaceutical services provider, and Kyoto Pharmaceutical University (KPU), a private pharmacy and science university, have announced a new joint program for clinical research and clinical trial management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry.

[Read More]

Biosimilars legislation approved in New Jersey

Wednesday, November 11, 2015

Legislation sponsored by Assembly Democrats of the New Jersey General Assembly (Pamela Lampitt, Daniel Benson, Shavonda Sumter, Nancy Pinkin, and Herb Conaway Jr., M.D.) to make it easier for consumers to obtain more cost-effective, “generic” versions of biological medicines used to treat conditions such as rheumatoid arthritis, anemia, psoriasis and various forms of cancer has been signed into law.

[Read More]

SCRS adds Icon as global impact partner

Monday, November 9, 2015

The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, has announced a two-year relationship with Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Icon will participate as a global impact partner (GIP) and align with 31 other sponsors, CROs and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.

[Read More]